From: Sildenafil for treating patients with COVID-19 and perfusion mismatch: a pilot randomized trial
Outcome | Sildenafil group (n = 20) | Placebo group (n = 20) | Total (n = 40) | P value |
---|---|---|---|---|
Clinical outcomes | ||||
In-hospital mortality (n, %) | 0 (0%) | 1 (5.0%) | 1 (2.5%) | > 0.99a |
Intensive care unit (ICU) admission (n, %) | 3 (15%) | 5 (25%) | 8 (20%) | 0.59a |
Initiation of high-flow nasal cannula (n, %) | 3 (15%) | 3 (15%) | 6 (15%) | 0.95a |
Initiation of invasive mechanical ventilation (n, %) | 0 (0%) | 4 (20%) | 4 (10%) | 0.04a |
Median duration of mechanical ventilation (days) (IQR) | – | 21 (8.5–36.5) | – | – |
Median ICU stay (days) (IQR) | 7 (7–8) | 15 (7–42) | 7.5 (7–28.5) | 0.46b |
Median hospital stay (days) (IQR) | 9 (7–12) | 12 (9–21) | 11 (8–14) | 0.04c |
Laboratory outcomes | ||||
Mean PaO2/FiO2 ratio one hour after treatment administration (SD) | 274 (230–338) | 267 (216–310) | 275 (230–314) | 0.56c |
Mean A-a gradient 1 h after treatment administration (SD) | 81.6 (44–124) | 104 (44–149) | 91.5 (32.7–175) | 0.56c |
Adverse events | ||||
Headache (n, %) | 2 (10%) | 5 (25%) | 7 (17.5%) | 0.41d |
Dizziness (n, %) | 4 (20%) | 2 (10%) | 6 (15%) | 0.66d |
Blurred vision (n, %) | 0 (0%) | 0 (0%) | 0 (0%) | – |
Flushing (n, %) | 2 (10%) | 0 (0%) | 2 (5%) | 0.49d |
Nausea (n, %) | 0 (0%) | 4 (20%) | 4 (10%) | 0.11d |
Nasal congestion (n, %) | 3 (15%) | 2 (10%) | 5 (12.5%) | > 0.99d |
Other (n, %) | 1 (5%) | 0 (0%) | 1 (2.5%) | > 0.99d |